- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
P.E.T.Net pharmaceuticals licenses technology
Technology for labeling beta-amyloid plaques, which may be useful in detecting and treating Alzheimer’s disease, has been licensed from the University of California, Los Angeles by P.E.T.Net pharmaceuticals. The Knoxville, TN, company plans to use
Technology for labeling beta-amyloid plaques, which may be useful in detecting and treating Alzheimer’s disease, has been licensed from the University of California, Los Angeles by P.E.T.Net pharmaceuticals. The Knoxville, TN, company plans to use the technology to develop its own diagnostic tests, as well as to participate in research partnerships with pharmaceutical companies. The tests being developed will utilize positron-emitting molecular probes specific to the plaques and neural tangles associated with Alzheimer’s disease.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
